TickerFacts.

Pelthos Therapeutics Inc. (PTHS): Cost of Revenue

Annual figures by period end, from SEC filings.

$3.99M
Year ended 2025-12-31
$9.27M
Trailing 12 months to 2026-06-30
2024-12-31: $02025-12-31: $3.99M$3.99M
2024-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$3.99Mn/a2026-03-19, From 2025-01-01
2024-12-31$0n/a2026-03-19, From 2024-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Pelthos Therapeutics Inc. (PTHS)2025-12-31$3.99Mn/a
LENZ Therapeutics, Inc. (LENZ)2025-12-31$418.0Kn/a
Lineage Cell Therapeutics, Inc. (LCTX)2024-12-31$334.0K-50.2%
Alpha Cognition Inc. (ACOG)2025-12-31$603.4Kn/a
Scilex Holding Co (SCLX)2025-12-31$10.60M-36.5%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$5.76M+622.3%
Kymera Therapeutics, Inc. (KYMR)2025-12-31$39.21M-16.7%
Protalix BioTherapeutics, Inc. (PLX)2025-12-31$26.99M+11.0%
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$931.0K+10.3%

Compare PTHS, LENZ, LCTX, ACOG side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗